Business Overview

Aflac Inc (NYSE: AFL) is a holding company best known for supplemental health and life insurance, sold under its iconic duck-branded marketing. Despite being headquartered in Columbus, Georgia, Aflac is unusual among US-listed insurers because the majority of its business and earnings come from Japan. The company operates through two primary reporting segments: Aflac Japan and Aflac U.S. Aflac Japan is one of the largest insurers in that market, selling cancer insurance, medical insurance, and other "third sector" supplemental products, along with some first-sector life products. Aflac U.S. sells voluntary supplemental coverage—accident, disability, critical illness, hospital indemnity, dental, vision, and life—largely at the worksite to employees through payroll deduction.

The core of how Aflac makes money is the classic insurance model with two engines. First is underwriting: it collects premiums from policyholders and pays out claims and benefits, aiming to keep claims plus expenses below premiums earned. Aflac's supplemental products typically pay cash benefits directly to the insured to offset out-of-pocket costs, which historically has supported relatively favorable and stable claims experience. Second is investment income: because policyholders pay premiums before claims come due, Aflac holds a large investment portfolio—heavily weighted toward fixed-income securities—and earns a spread on those assets. Profit is therefore a combination of underwriting margin and net investment income, and a meaningful portion of that profit is returned to shareholders through dividends and consistent share repurchases.

Financial Trends

Aflac's financial profile reflects a mature, cash-generative insurer rather than a high-growth company. Revenue is driven by net earned premiums plus net investment income, and the qualitative story is one of stability and capital return rather than rapid top-line expansion. Earned premiums in Japan have faced structural headwinds because much of the in-force block is older, high-margin business that runs off over time, while newer sales mix has shifted; investors should think in terms of policy persistency, new sales momentum, and the balance between in-force runoff and new business.

• Two profit levers: the benefit ratio (claims relative to premiums) and the expense ratio drive underwriting margin, while net investment income drives the spread. Both segments tend to run attractive pretax profit margins by insurance standards.
• Heavy yen exposure: because Japan dominates earnings, reported results in US dollars swing with the yen/dollar exchange rate. Currency translation can make growth look better or worse than the underlying business, which is why management emphasizes results on a constant-currency basis.
• Balance sheet structure: a very large fixed-maturity investment portfolio funded by insurance reserves (policyholder liabilities). Book value and equity are sensitive to interest rates and unrealized gains/losses on securities.
• Capital return focus: Aflac is known as a dependable dividend grower with a long track record of raising its payout, supplemented by ongoing buybacks. Free capital generation and the holding company's ability to upstream cash from regulated subsidiaries are central to the equity story.

What to Watch in the Filings

When reading Aflac's 10-K and 10-Q, the segment-level disclosures matter more than the consolidated headline numbers. Key areas to focus on:

• Segment results for Aflac Japan vs. Aflac U.S.: watch net earned premiums, new annualized premium sales, and pretax adjusted earnings for each. Japan's in-force runoff versus US sales growth is the central tension.
• Benefit (claims) ratio and expense ratio trends: these show whether underwriting margins are holding. Look for management commentary in the MD&A on persistency (lapse rates) and product mix.
• Net investment income and the investment portfolio: review credit quality, asset allocation, exposure to commercial real estate and below-investment-grade holdings, and any impairments. Aflac also discloses yen-denominated and dollar-denominated investment buckets.
• Foreign currency effects: the filings break out the impact of yen translation and any hedging of the net investment in Japan. Compare reported growth to constant-currency figures.
• Capital and liquidity: watch the Japan solvency margin ratio (SMR), US RBC ratios, holding-company liquidity, and dividends/buybacks. 8-Ks frequently announce dividend increases, buyback authorizations, and quarterly earnings.
• Accounting: note the long-duration insurance accounting (LDTI) framework, which affects how reserves and deferred acquisition costs are measured and can introduce volatility in reported results.

Key Risks

• Japan concentration: a large share of premiums and earnings come from a single country, so Japanese economic conditions, demographics (an aging, shrinking population), regulation, and competition heavily influence results.
• Currency risk: the yen/dollar exchange rate materially affects US-dollar-reported revenue, earnings, and book value, independent of underlying business performance.
• Interest-rate and investment risk: as a large fixed-income investor, Aflac is exposed to low rates compressing reinvestment yields, rising rates pressuring portfolio values, and credit losses—particularly in areas like commercial real estate and lower-rated bonds.
• Sales and distribution risk: US growth depends on worksite/payroll enrollment, and disruptions to employment, benefit broker relationships, or its distribution alliances (including its bank and partner channels in Japan) can slow new business.
• Product and persistency risk: heavy reliance on cancer and medical supplemental products means changes in medical costs, claims experience, or policyholder lapse behavior can move margins.
• Regulatory risk: Aflac operates under both Japanese and US insurance regulators, with solvency, capital, consumer-protection, and tax rules that can change.
• Competition: the supplemental and voluntary benefits markets are competitive, with large domestic and Japanese insurers vying for share, which can pressure pricing and growth.

Frequently Asked Questions